Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program |
| |
| Authors: | Jerzy P. Szaflarski Orrin Devinsky Merrick Lopez Yong D. Park Pilar Pichon Zentil Anup D. Patel Elizabeth A. Thiele Robert T. Wechsler Daniel Checketts Farhad Sahebkar |
| |
| Affiliation: | 1. Department of Neurology, UAB Epilepsy Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA;2. Comprehensive Epilepsy Center, NYU Langone Health, New York, New York, USA;3. Pediatric Critical Care Medicine, Loma Linda University Children's Hospital, Loma Linda, California, USA;4. Pediatric Neurology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA;5. Pediatric Neurology, Loma Linda University Children's Hospital, Loma Linda, California, USA;6. Neurology and Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA;7. Pediatric Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA;8. Consultants in Epilepsy & Neurology, and Idaho Comprehensive Epilepsy Center, Boise, Idaho, USA;9. Biostatistics, Jazz Pharmaceuticals, Inc., Carlsbad, California, USA;10. Clinical Development, Jazz Pharmaceuticals, Inc., Carlsbad, California, USA |
| |
| Abstract: | Objective Cannabidiol (CBD) expanded access program, initiated in 2014, provided add-on CBD to patients with treatment-resistant epilepsies (TREs) at 35 US epilepsy centers. Prior publications reported results through December 2016; herein, we present efficacy and safety results through January 2019. Methods Patients received plant-derived highly purified CBD (Epidiolex®; 100 mg/ml oral solution), increasing from 2 to 10 mg/kg/day to tolerance or maximum 25–50 mg/kg/day dose, depending on the study site. Efficacy endpoints included percentage change from baseline in median monthly convulsive and total seizure frequency and ≥50%, ≥75%, and 100% responder rates across 12-week visit windows for up to 192 weeks. Adverse events (AEs) were documented at each visit. Results Of 892 patients in the safety analysis set, 322 (36%) withdrew; lack of efficacy (19%) and AEs (7%) were the most commonly reported primary reasons for withdrawal. Median (range) age was 11.8 years (range = 0–74.5), and patients were taking a median of three (range = 0–10) antiseizure medications (ASMs) at baseline; the most common ASMs were clobazam (47%), levetiracetam (34%), and valproate (28%). Median top CBD dose was 25 mg/kg/day; median exposure duration was 694 days. Median percentage reduction from baseline ranged 50%–67% for convulsive seizures and 46%–66% for total seizures. Convulsive seizure responder rates (≥50%, ≥75%, and 100% reduction) ranged 51%–59%, 33%–42%, and 11%–17% of patients across visit windows, respectively. AEs were reported in 88% of patients and serious AEs in 41%; 8% withdrew because of an AE. There were 20 deaths during the study deemed unrelated to treatment by the investigator. The most common AEs (≥20% of patients) were diarrhea (33%), seizure (24%), and somnolence (23%). Significance Add-on CBD was associated with sustained seizure reduction up to 192 weeks with an acceptable safety profile and can be used for long-term treatment of TREs. |
| |
| Keywords: | antiseizure medications convulsive seizures treatment-resistant seizures |
|
|
